Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Larru, Beatriz ^a   de Mendoza, Carmen ^b   Bellón, José Ma ^a   de José, Ma Isabel ^b   Mellado, Ma José ^b   Soriano, Vincent ^b   Muñoz Fernandez, Ma Angeles ^a   Ramos, José T ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DNA; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; VIRUS RNA;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; SALVAGE THERAPY; SPAIN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK ASSESSMENT;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34347390840     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-55     Document Type: Article

References (18)

1. Foster C Lyall EG Children with HIV: Improved mortality and morbidity with combination antiretroviral therapy Curr Opin Infect Dis 2005 18 3 253-259 10.1097/01.qco.0000168387.24142.cf 15864104
2. Frenkel LM Tobin NH Understanding HIV-1 drug resistance Ther Drug Monit 2004 26 2 116-121 10.1097/00007691-200404000-00005 15228150
3. Clavel F Hance AJ HIV drug resistance N Engl J Med 2004 350 10 1023-1035 10.1056/NEJM2ra025195 14999114
4. Luzuriaga K McManus M Mofenson L Britto P Graham B Sullivan JL A trial of three antiretroviral regimens in HIV-1-infected children N Engl J Med 2004 350 24 2471-2480 10.1056/NEJMoa032706 15190139
5. Resino S J MB Gurbindo D Tomas Ramos J Antonio Leon J Jose Mellado M Angeles Munoz-Fernandez M Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: An observational study Clin Infect Dis 2003 37 9 1216-1225 10.1086/378804 14557967
6. Gibb DM Walker AS Kaye S De Rossi A Ait-Khaled M Pillay D Munoz-Fernandez MA Loveday C Compagnucci A Dunn DT Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/ lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial) Antivir Ther 2002 7 4 293-303 12553485
7. Loutfy MR Raboud JM Walmsley SL Saskin R Montaner JS Hogg RS Thompson CA Harrigan PR Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens Antivir Ther 2004 9 4 595-602 15456091
8. Delaugerre C Teglas JP Treluyer JM Vaz P Jullien V Veber F Rouzioux C Chaix ML Blanche S Predictive Factors of Virologic Success in HIV-1-Infected Children Treated With Lopinavir/Ritonavir J Acquir Immune Defic Syndr 2004 37 2 1269-1275 10.1097/01.qai.0000137408.78031.37 15385734
9. Bartlett JG New guidelines for antiretroviral therapy from the IAS-USA and DHHS Hopkins HIV Rep 2000 12 3 6-7 12184234
10. Resino S Bellon JM Ramos JT Navarro ML Martin-Fontelos P Cabrero E Munoz-Fernandez MA Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children Pediatr Infect Dis J 2004 23 10 923-930 10.1097/01.inf.0000142170.52155.7f 15602192
11. Resino S Bellon JM Ramos JT Gonzalez-Rivera M de Jose MI Gonzalez MI Gurbindo D Mellado MJ Cabrero E Munoz-Fernandez MA Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: A prospective cohort study J Antimicrob Chemother 2004 54 5 921-931 10.1093/jac/dkh431 15472006
12. Ramos JT De Jose MI Duenas J Fortuny C Gonzalez-Montero R Mellado MJ Mur A Navarro M Otero C Pocheville I Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals Pediatr Infect Dis J 2005 24 10 867-873 10.1097/ 01.inf.0000180574.18804.90 16220083
13. Delaugerre C Teglas JP Treluyer JM Vaz P Jullien V Veber F Rouzioux C Chaix ML Blanche S Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir J Acquir Immune Defic Syndr 2004 37 2 1269-1275 10.1097/01.qai.0000137408.78031.37 15385734
14. Perez-Elias MJ Garcia-Arota I Munoz V Santos I Sanz J Abraira V Arribas JR Gonzalez J Moreno A Dronda F Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study Antivir Ther 2003 8 6 577-584 14760891
15. Gallego O Martin-Carbonero L Aguero J de Mendoza C Corral A Soriano V Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals J Virol Methods 2004 121 1 115-118 10.1016/ j.jviromet.2004.06.003 15350741
16. Torti C Quiros-Roldan E Monno L Patroni A Saracino A Angarano G Tinelli C Lo Caputo S Tirelli V Mazzotta F Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients J Med Virol 2004 74 1 29-33 10.1002/ jmv.20142 15258965
17. Saracino A Monno L Locaputo S Torti C Scudeller L Ladisa N Antinori A Sighinolfi L Chirianni A Mazzotta F Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: An open-label, randomized, multicenter study (PhenGen) J Acquir Immune Defic Syndr 2004 37 5 1587-1598 10.1097/00126334-200412150-00011 15577415
18. Barreiro P Camino N de Mendoza C Valer L Nunez M Martin-Carbonero L Gonzalez-Lahoz J Soriano V Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors Int J Antimicrob Agents 2002 20 6 438-443 10.1016/ S0924-8579(02)00250-9 12458138